More information about ACASTI PHARMA INC.

Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Acasti’s lead product candidate is CaPre® (omega-3 phospholipid), which Acasti is developing initially for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL). Acasti believes the potential exists to expand CaPre’s indication to mild to moderate hypertriglyceridemia (200 – 499 mg/dL) with the likelihood of additional clinical trials being required such as comparative studies and outcome trials, assuming positive outcome study data in the next two years from two competitors. In addition, Acasti may seek to identify new potential indications for CaPre that may be appropriate for future studies and pipeline expansion. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia. Market research commissioned by Acasti* suggests there is an important market need for an effective, safe and well-absorbing omega-3 therapeutic with a positive impact on the major lipids associated with cardiovascular disease risk. Since August 2008, Acasti is focused on addressing this important unmet market need.